From papanicolaou to papillomaviruses: Evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination

Journal of the National Cancer Institute

Volumn 105, Issue 20, 2013, Pages 1524-1526

  Safaeian, Mahboobeh ^a   Sherman, Mark E ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Life Sciences Bldg 06   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; WART VIRUS VACCINE;

CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; EDITORIAL; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOCYTOCHEMISTRY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KI-67 ANTIGEN; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84886081214     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt267     Document Type: Editorial

References (13)

1. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide. Asian Pac J Cancer Prev. 2009;10:645-650.
2. Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER, Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002 Obstet Gynecol. 2007;109:360-370.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
4. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97: 3133-3275.
5. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust. 2006;185:482-486.
6. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-672.
7. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. 2013.
8. Waxman AG, Chelmow D, Darragh TM, Lawson H, Moscicki AB. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 2012;120:1465-1471.
9. Darragh TM, Colgan TJ, Thomas CJ, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32:76-115.
10. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013;14:168-176.
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
12. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1444-1451.
13. Safaeian M, Porras C, Yuanji P, Kreimer AR, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prevention Research. 2013. In Press.